Abstract
Background Understanding risk factors for death in Covid-19 is key to providing good quality clinical care. Due to a paucity of robust evidence, we sought to assess the presenting characteristics of patients with Covid-19 and investigate factors associated with death.
Methods Retrospective analysis of adults admitted with Covid-19 to Royal Oldham Hospital, UK. Logistic regression modelling was utilised to explore factors predicting death.
Results 470 patients were admitted, of whom 169 (36%) died. The median age was 71 years (IQR 57–82), and 255 (54.3%) were men. The most common comorbidities were hypertension (n=218, 46.4%), diabetes (n=143, 30.4%) and chronic neurological disease (n=123, 26.1%). The most frequent complications were acute kidney injury (n=157, 33.4%) and myocardial injury (n=21, 4.5%). Forty-three (9.1%) patients required intubation and ventilation, and 39 (8.3%) received non-invasive ventilation Independent risk factors for death were increasing age (OR per 10 year increase above 40 years 1.87, 95% CI 1.57-2.27), hypertension (OR 1.72, 1.10-2.70), cancer (OR 2.20, 1.27-3.81), platelets <150×103/µL (OR 1.93, 1.13-3.30), C-reactive protein ≥100 µg/mL (OR 1.68, 1.05-2.68), >50% chest radiograph infiltrates, (OR 2.09, 1.16-3.77) and acute kidney injury (OR 2.60, 1.64-4.13). There was no independent association between death and gender, ethnicity, deprivation level, fever, SpO2/FiO2 (oxygen saturation index), lymphopenia or other comorbidities.
Conclusions We characterised the ‘first wave’ of patients with Covid-19 in one of England’s highest incidence areas, determining which factors predict death. These findings will inform clinical and shared decision making, including the use of respiratory support and therapeutic agents.
Summary Increasing age, hypertension, cancer, platelets <150×103/µL, CRP≥100 µg/mL, >50% chest radiograph infiltrates, and acute kidney injury predict in-hospital death from Covid-19, whilst gender, ethnicity, deprivation level, fever, SpO2/FiO2 (oxygen saturation index), lymphopenia and other comorbidities do not.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Northern Care Alliance (NCA) Research Management and Support (RM&S) team and did not require the approval from the NHS Health Research Authority (HRA) as the institutional oversight body waived the requirement for NHS ethical approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data may be available from the authors upon request, dependent on institutional approval.